Public Company News

ROKAE delivers its 10,000th humanoid force-controlled arm

Milestone delivery highlights industrial adoption, with ROKAE robots deployed at Schaeffler's Lighthouse Factory in China BEIJING, Oct. 26, 2026 /PRNewswire/ -- ROKAE Robotics (HKEX: 3752) has delivered its 10,000th humanoid force-controlled arm, marking a milestone in...

2026-10-27 00:00 22852

FF EAI Robotics Ecosystem Completed its Acquisition of the Robotics Business of Faraday Future, Establish Nasdaq-Listed Humanoid and Bionic Robotics Platform

* FFR expects October 2026 robot sales and shipments to exceed 300 units, setting a new monthly record and bringing cumulative shipments to more than 1,100 units, while continuing to deliver robots at a positive unit gross margin LOS ANGELES, Oct. 26, 2026 /PRNewswire/ -- FF EAI Robotics Ecosys...

2026-10-26 23:30 7567

Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026

CAMBRIDGE, Mass., Oct. 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human Phase 1 data for ISM6331, its investigational oral pan-TEAD inhibitor designed using Chemistry42 gener...

2026-10-26 21:00 5853

WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model

SHANGHAI, Oct. 26, 2026 /PRNewswire/ -- WuXi AppTec (Stock Codes: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first three quarters ending September 30, 2026 ("Reporting Peri...

2026-10-26 17:25 6155

Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma

SAN FRANCISCO and SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2026-10-26 17:18 3100

111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee

SHANGHAI, Oct. 26, 2026 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising three independent directors, Mr. Jian Sun, who is the chairman of...

2026-10-26 16:00 3057

Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026

SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the preliminary positive research results of the investigator-initiated trial (CT041-CG4010, NCT06857786) in China o...

2026-10-26 08:30 6663

2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

* The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its potential clinical value across treatment settings. SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PR...

2026-10-26 08:00 5189

2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabol...

2026-10-25 14:00 5680

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabol...

2026-10-25 14:00 5460

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 /PRNewswire/ -- Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a re...

2026-10-24 09:26 10232

REJURAN® COSMETICS Expands U.S. Retail Presence Through Costco's First-Ever Beauty Table Program

The premium Korean skincare brand introduces a Costco member set featuring its c-PDRN®-powered Turnover Ampoule SEOUL, South Korea, Oct. 23, 2026 /PRNewswire/ -- REJURAN® COSMETICS is expanding its U.S. retail presence through Costco's new Beauty Table program, bringing its c-PDRN® skincare to m...

2026-10-24 00:07 6167

AMTD IDEA's Total Assets Exceeded US$2.6 Billion as of 2026 Half Year and Sets Forth Clear Growth Path in Global Hospitality

* Revenue from contracts with customers grew by 32.1% to US$32.0 million * Hospitality arm's revenue surged by 59.8% * Total Assets amounted to US$2.6 billion (US$4.5/share) * Net Assets amounted to US$1.9 billion (US$3.3/share) PARIS and NEW YORK and SINGAPORE, Oct. 23, 2026 /PRNewswire...

2026-10-23 20:24 14190

Coreline Soft Receives U.S. FDA 510(k) Clearance for AVIEW Aorta Metrics, Expanding Its Chest CT AI Portfolio in the U.S.

* Secures its 13th FDA 510(k) clearance, expanding its U.S. portfolio from lung nodule detection and coronary artery calcium (CAC) analysis to quantitative aortic assessment * Enables automated aortic segmentation and diameter measurements across anatomical regions, broadening the quantitativ...

2026-10-23 20:00 4474

2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS

* Registrational Phase 3 G-HOPE-001 Study Met Both Primary Endpoints, Demonstrating Statistically Significant and Clinically Meaningful Overall Survival and Progression-Free Survival Benefits in Previously Treated, CLDN18.2-positive Gastric Cancer * Arcotatug Tavatecan Demonstrated a Favorabl...

2026-10-23 20:00 3780

JinkoSolar Completes Name Change to Jinko Holdings Limited

ADSs continue to trade under "JKS"; Company to Enhance Transparency on Strategic Investment Portfolio SHANGRAO, China, Oct. 23, 2026 /PRNewswire/ -- Jinko Holdings Limited ("Jinko Holdings" or the "Company") (NYSE: JKS), formerly JinkoSolar Holding Co., Ltd., today announced that its new company...

2026-10-23 18:03 3057

Amber International Holding Limited Announces Results of the Annual General Meeting on October 23, 2026

SINGAPORE, Oct. 23, 2026 /PRNewswire/ -- Amber International Holding Limited ("Amber International" or the "Company") (NASDAQ: AMBR) today announced the results of the Company's annual general meeting of shareholders (the "AGM") held in Singapore today. At the AGM, shareholders approved, ratifie...

2026-10-23 17:45 3513

LianLian Global and PayPal Power Cross-Border Payouts for Social Commerce, Marketplace, and eCommerce Customers

Social commerce, marketplaces and eCommerce players served by LianLian Global can now pay creators, influencers, developers, and independent contractors directly to their PayPal and Venmo wallets. NEW YORK, Oct. 22, 2026 /PRNewswire/ -- LianLian Global  today anno...

2026-10-23 10:27 12777

ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026

SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 /PRNewswire/ --  ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate in BIO-...

2026-10-23 10:07 2899

Scage Future Announces Effective Date for ADS Ratio Change

NANJING, China, Oct. 22, 2026 /PRNewswire/ -- Scage Future ("Scage Future" or the "Company") (Nasdaq: SCAG), a provider of new energy and zero-emission heavy-duty commercial vehicles and e-fuel solutions, today announced the effective date and new CUSIP number for the previously announced change ...

2026-10-23 08:05 7099
1 ... 891011121314 ... 745